1 minute read
TABLE OF CONTENTS
from Access to New Cures & Innovative Care for Medicaid Patients: Examining Challenges and Opportunities
ACKNOWLEDGMENTS This white paper was financially supported by The Assistance Fund (TAF).
TAF is a nonprofit 501(c)(3) independent charitable assistance organization that helps patients by providing financial assistance with copayments, coinsurance, deductible, and other healthrelated expenses. TAF currently manages over 70 disease programs, all of which cover FDA-approved medications that treat a specific disease. TAF is committed to improving the lives of patients by easing the burden of high-cost therapies, including cell and gene therapies, and supporting policies which will improve access to these life-saving treatments over time. For more information, please visit www.tafcares.org.
Leavitt Partners acknowledges the valuable insights and perspective of the more than 45 experts whom we interviewed as part of the research for this project. The individuals we interviewed provided insightful observations and thoughtful recommendations on the wide array of challenges and diverse opportunities related to the coverage and reimbursement of cell and gene therapies in Medicaid.
